For the more demanding in vivo application the nanoliposomal EphA2-targeted therapeutic EPHARNA (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; DOPC) was developed, leading to efficient reduction in EphA2 expression and tumor growth in an ovarian cancer mouse xenograft model [50]. The gene discussed is EPHA2; the disease is ovarian carcinoma.